Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: Incidence, risk factors, and prognostic prediction

Journal of Clinical Gastroenterology

Volumn 45, Issue 6, 2011, Pages 556-562

  Hsin, I Fang ^a,b   Hsu, Chia Yang ^a,b   Huang, Hui Chun ^a,b   Huang, Yi Hsiang ^a,b   Lin, Han Chieh ^a,b   Lee, Rheun Chuan ^a,b   Chiang, Jen Huey ^a,b   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b   Lee, Shou Dong ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

ascites; hepatocellular carcinoma; liver cirrhosis; liver failure; transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; GELFOAM;

ADULT; AGED; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

AGED; ANTINEOPLASTIC AGENTS; ASCITES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INCIDENCE; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 79958827090     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318210ff17     Document Type: Article

References (38)

1. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
2. Department of Health, Taiwan, the Republic of China. Cancer Registry Anual Report 2007.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. (Pubitemid 34183954)
4. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239-245.
5. Huang YH, Chen CH, Chang TT, et al. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int. 2004;24:419-424.
6. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171. (Pubitemid 34454013)
7. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(suppl 1):S20-S37.
8. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741-749.
9. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256-1261.
10. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol. 2001;34:46-52. (Pubitemid 32102551)
11. Dvorchik I, Carr BI. A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. Cancer Detect Prev. 2007;31:154-160. (Pubitemid 46669814)
12. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469. (Pubitemid 44142456)
13. Ueno K, Miyazono N, Inoue H, et al. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer. 2000;88:1574-1581. (Pubitemid 30183142)
14. Hsu CY, Huang YH, Su CW, et al. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J Clin Gastroenterol. 2010;44:e171-e177.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. (Pubitemid 43112690)
16. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988;8:12-25.
17. Huang YS, Chiang JH, Wu JC, et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol. 2002;97:1223-1227.
18. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442. (Pubitemid 36152543)
19. Carr BI, Buch SC, Kondragunta V, et al. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008; 23(8 Pt 1):1259-1266.
20. Trevisani F, De Notariis S, Rossi C, et al. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol. 2001;32:383-389. (Pubitemid 32378268)
21. Katsushima S, Inokuma T, Oi H, et al. Acute hepatic failure following transcatheter arterial embolization for the treatment of hepatocellular carcinoma. Digestion. 1997;58:189-195. (Pubitemid 27163171)
22. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;1:181-184.
23. Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 1993;34:1598-1600. (Pubitemid 23341855)
24. Yuen MF, Chan AO, Wong BC, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol. 2003;98:1181-1185. (Pubitemid 36733785)
25. Savastano S, Miotto D, Casarrubea G, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol. 1999;28:334-340. (Pubitemid 29246409)
26. Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008; 112:352-361.
27. Paye F, Farges O, Dahmane M. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg. 1999;86:176-180. (Pubitemid 29090179)
28. Cardenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab. 2003;17:607-622.
29. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151-1157.
30. Pietrosi G, Miraglia R, Luca A, et al. Arterial chemoembolization/ embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. J Vasc Interv Radiol. 2009;20:896-902.
31. Hirakawa M, Iida M, Aoyagi K, et al. Gastroduodenal lesions after transcatheter arterial chemo-embolization in patients with hepatocellular carcinoma. Am J Gastroenterol. 1988;83:837-840.
32. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology. 2001;34(4 Pt 1):671-676. (Pubitemid 32927990)
33. Gatta A, Merkel C, Amodio P, et al. Development and validation of a prognostic index predicting death after upper gastrointestinal bleeding in patients with liver cirrhosis: a multicenter study. Am J Gastroenterol. 1994;89:1528-1536. (Pubitemid 24313047)
34. Hsu CY, Huang YH, Hsia CY, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006-3014.
35. Martins A, Cortez-Pinto H, Marques-Vidal P, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687. (Pubitemid 43994787)
36. Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring system. J Hepatol. 2010;53:108-117.
37. Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747-1752. (Pubitemid 34241113)
38. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25. (Pubitemid 44900485)